Wuhan Langlai Technology Development

About Wuhan Langlai Technology Development

Wuhan Langlai Technology Development, operating as Createrna Science & Technology, is a clinical-stage biotechnology firm founded in May 2013. The company operates as a spin-off of Wuhan QR Pharma and has established itself as a key player in the development of small molecule medicines targeting clinically significant diseases. Leading the company is CEO Dr. Yaning Wang, who brings extensive experience from his previous role as the Director of the Division of Pharmacometrics at the U.S. Food and Drug Administration (FDA). His 18-year tenure at the FDA, coupled with a Ph.D. in Pharmaceutics and a master's degree in Statistics, provides a deep regulatory and scientific foundation for Createrna's drug development programs.

The company's business model is centered on a dual-driven strategy, simultaneously advancing its research and development pipeline and building its technological platforms. Createrna manages the entire drug development lifecycle, from initial proof-of-concept and candidate screening to preclinical development and multi-phase clinical trials. Its revenue generation is anticipated through intellectual property licensing, collaborations with major pharmaceutical companies, and the eventual commercialization of its proprietary drugs. The company's structure includes R&D centers in Wuhan and Shanghai, a translational medicine center in Wuhan, and an international center in Maryland, USA, which handles business development and FDA applications.

Createrna's therapeutic focus is diversified across several areas with high unmet medical needs. Its pipeline includes treatments for cardiovascular diseases like essential hypertension and chronic heart failure; kidney diseases such as IgA nephropathy and diabetic nephropathy; respiratory conditions including chronic cough and idiopathic pulmonary fibrosis; and various inflammatory diseases. The company has over 20 pipelines in different development stages, with eight having advanced to clinical trials (Phase 1 to Phase 3) and another four in preclinical development. In June 2023, Createrna secured a significant Series A financing round of RMB 500 million (approximately $70.4M), co-led by investors including Lilly Asia Ventures and Vivo Capital, to accelerate its R&D and clinical studies.